Description of the standard dosage and individualized adjustment plan of DaliRasheng (Keweike)

Daridorexant is an oral dual sleep-promoting neuropeptide receptor (DORA) antagonist, mainly used to treat insomnia patients' difficulty in falling asleep and maintaining sleep disorders. It helps patients fall asleep and prolong sleep time by inhibiting the activity of wake-promoting neuropeptide (orexin) receptors. According to clinical studies and drug instructions, the standard dose of DaliRasen is 10 mg or 25 mg taken orally once a day, about 30 minutes before bedtime, and should not be taken with a large amount of food to avoid delayed absorption.

For elderly patients 65 years old and above, because their metabolic capacity may decrease and drug exposure in the body increases, it is recommended to start with a low dose (10 mg) and decide whether to adjust the dose after assessing tolerance. Elderly patients are often more susceptible to side effects such as excessive sedation, falls, or decreased concentration, so safety needs to be fully considered in individualized adjustments.

Patients with moderately impaired liver function (Child-Pugh B grade) should carefully select low doses and undergo close monitoring when using dalirasam. Sufficient safety data are lacking and it is generally recommended to avoid use in patients with severe hepatic impairment (Child-Pugh C grade). For patients with moderately to severely impaired renal function (eGFR <60 mL/min/1.73m²), although the reduction in drug clearance is limited, it is recommended to start with a low dose and observe drug tolerance.

In clinical application, the dose of dalirasin should be individually adjusted based on the patient's severity of sleep problems, tolerance and side effects. Patients who take the drug for the first time usually start with a low dose and observe the time it takes to fall asleep, the frequency of nighttime awakenings, and the mental state of the next day. If tolerated well and sleep improvement is insufficient, the dose may be increased under the guidance of a physician. Patients should avoid co-administration with other central depressant drugs and maintain a good sleep environment and routine to maximize drug efficacy and reduce risks. Through scientific dose adjustment and follow-up, DaliRasen can improve sleep quality while ensuring safety.

Reference materials:https://www.drugs.com/